September 2018- Volume 14, Issue 9
In this Issue
Business & Government Policy
Patent Docs: Allergan, a Mohawk tribe and the USPTO
Patent Docs: Allergan, a Mohawk tribe and the USPTO
Federal Circuit decision addresses dispute between Allergan and the St. Regis Mohawk Tribe, tackling the issue of sovereign immunity
X-SCID expertise
X-SCID expertise
Mustang Bio and St. Jude enter license agreement
Reducing cancer trial barriers
Reducing cancer trial barriers
Two research organizations submit recommendations to FDA aimed at greater patient participation in trials
On the cutting edge
On the cutting edge
A roundup of instrumentation, software and other tools and technology news
It’s all in the delivery
It’s all in the delivery
Checking out the news in drug delivery advancements
Q&A
Q&A: SK Life Science and the central nervous system
Q&A: SK Life Science and the central nervous system
We speak with Dr. Marc Kamin, chief medical officer of SK Life Science, about the company and CNS disorder therapeutics
Diagnostics
HeadsUp for cystic fibrosis
HeadsUp for cystic fibrosis
Study to assess biomarkers associated with onset of pulmonary problems and validate diagnostic for self-monitoring
Predicting checkpoint blocker response
Predicting checkpoint blocker response
Study finds melanoma biomarkers that could help in tailoring immunotherapy
The earlier, the better
The earlier, the better
Precision’s Epiontis ID diagnostic detects many rare, severe immune diseases in newborns
Accurate annotations
Accurate annotations
Bicoastal startup launches NGS product for pathogen detection
Clinical Trials
Out of the starting gate
Out of the starting gate
A roundup of clinical trial startups and initial breakthroughs
Zogenix announces positive results for ZX008 in Dravet syndrome
Zogenix announces positive results for ZX008 in Dravet syndrome
Statistically significant convulsive seizure reduction seen, and all key secondary endpoints met
Mogamulizumab makes a mark
Mogamulizumab makes a mark
Kyowa Kirin announces results of Phase 3 clinical study published in Lancet Oncology
Conquering Crohn’s disease
Conquering Crohn’s disease
Promising Phase 3 test results give hope for those with the gastrointestinal disorder
Initial exuberance overshadowed by doubt
Initial exuberance overshadowed by doubt
Promising results from Alzheimer’s drug wither under closer scrutiny
Preclinical
Good news for Siamab with Stn
Good news for Siamab with Stn
New antigen target shows promise against ovarian cancer
Article elucidates ITI-214’s mechanism of action
Article elucidates ITI-214’s mechanism of action
Modulation of adenosine A2B receptor signaling pathway increases cardiac contractility without increasing intracellular calcium
Making the (pre)clinical rounds
Making the (pre)clinical rounds
A collection of news of recently published papers
Certis partners with Reveal Biosciences
Certis partners with Reveal Biosciences
Duo will offer advanced preclinical oncology services
Research & Development
Biomarker for breast cancer
Biomarker for breast cancer
Researchers identify a histone that could have significance in treating aggressive breast cancer
Tuning in to stereochemistry
Tuning in to stereochemistry
Scripps, Bristol-Myers Squibb scientists reveal a method to control thiophosphate linkages in nucleosides
Decoding how living tissues get their flexibility
Decoding how living tissues get their flexibility
MIT study reveals atomic structure of tropoelastin, showing what goes wrong in some diseases
Sustaining a market edge
Sustaining a market edge
MilliporeSigma, InnoCore enter into agreement to provide SynBiosys biodegradable polymer platform
Double the sequencing
Double the sequencing
Mount Sinai combines DNA and RNA sequencing to pinpoint treatment options for multiple myeloma patients
Discovery
CMPK2 inhibitors vs. chronic inflammation
CMPK2 inhibitors vs. chronic inflammation
Blocking CMPK2 enzyme could mean relief for a host of conditions
Blocking alcohol addiction and easing withdrawal
Blocking alcohol addiction and easing withdrawal
Scripps Research scientists find novel pathway in the receptor GPR139
Immatics and Genmab partner on next-gen cancer immunotherapies
Immatics and Genmab partner on next-gen cancer immunotherapies
Companies combine proprietary tech to create bispecific therapies against novel tumor targets
New data about the presence of prions
New data about the presence of prions
The identification of prion-like domains in multiple viral strains points to new areas to explore
Back to the beginning
Back to the beginning
Cells reverting to ‘fetal program’ may accelerate wound healing
Special Reports
Special Report on Stem Cells: The next generations
Special Report on Stem Cells: The next generations
Are stem cells key to fighting infertility?
Feature
ASHG 2018 show preview: Covering the breadth of human genetics in San Diego
ASHG 2018 show preview: Covering the breadth of human genetics in San Diego
American Society of Human Genomics Annual Meeting 2018 to showcase the latest on the human genome
Contract Services
LifeSci launches LifeSci Strategic Partnering and Analytics
LifeSci launches LifeSci Strategic Partnering and Analytics
New offering will give clients expertise and assistance in business development and market analytics
Catalent snaps up Juniper Pharmaceuticals
Catalent snaps up Juniper Pharmaceuticals
$133-million deal adds European Early Development Center of Excellence to global network
Riding the Seventh Wave to future growth
Riding the Seventh Wave to future growth
BASi acquires Missouri-based contract lab Seventh Wave, expanding service offerings, doubling clients
Editor's Focus
Editor’s focus: A ‘personalized’ problem in the public space
Editor’s focus: A ‘personalized’ problem in the public space
Way too many people in the United States still don’t know what personalized medicine is, and that’s a problem we need to overcome before the misinformation creeps in too much
Commentary
Out of order: Just being social
Out of order: Just being social
We’ve put a greater emphasis on our social media presence lately, and you might want to do the same if you haven’t already, not to mention visit us online
Guest commentary: DNA sequencing is cancer’s next frontier
Guest commentary: DNA sequencing is cancer’s next frontier
In the quest for personalized medicine to become reality, next-generation sequencing is key
